Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations.
Int J Chron Obstruct Pulmon Dis
; 4: 119-25, 2009.
Article
en En
| MEDLINE
| ID: mdl-19436693
ABSTRACT
Currently available long-acting inhaled bronchodilators (tiotropium, salmeterol, formoterol) have demonstrated beneficial effects on exacerbations in placebo-controlled trials. However, there have been no direct comparisons of these drugs with exacerbations as the primary outcome and consequently COPD treatment guidelines do not indicate a preference for either bronchodilator. Therefore, an international, randomized, double-blind, double-dummy, parallel-group clinical trial has been designed to investigate the comparative efficacy of 2 long-acting bronchodilators tiotropium 18 microg daily and salmeterol 50 microg bid on exacerbations. The trial will include at least 6800 randomized patients with diagnosis of COPD, >or= 10 pack-year history of smoking, post-bronchodilator FEV(1)
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Proyectos de Investigación
/
Derivados de Escopolamina
/
Broncodilatadores
/
Agonistas Adrenérgicos beta
/
Antagonistas Colinérgicos
/
Enfermedad Pulmonar Obstructiva Crónica
/
Albuterol
/
Pulmón
Tipo de estudio:
Clinical_trials
/
Guideline
/
Prognostic_studies
Límite:
Adult
/
Aged
/
Humans
/
Middle aged
Idioma:
En
Revista:
Int J Chron Obstruct Pulmon Dis
Año:
2009
Tipo del documento:
Article
País de afiliación:
Alemania